INVESTIGADORES
PEREZ LLORET Santiago
artículos
Título:
Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Autor/es:
OLIVIER RASCOL; SANTIAGO PEREZ LLORET
Revista:
EXPERT OPINION ON PHARMACOTHERAPY
Editorial:
INFORMA HEALTHCARE
Referencias:
Año: 2009 vol. 10 p. 677 - 691
ISSN:
1465-6566
Resumen:
BACKGROUND: Rotigotine
is a non-ergot dopamine agonist that has been developed as a new
transdermal formulation, and is indicated for use in early (USA and
Europe) and advanced (Europe only) Parkinson's disease (PD). The
potential advantages of the rotigotine patch include immediacy of effect
onset as intestinal absorption in unneeded, constant drug delivery, and
ease of use via application of a once-daily adhesive patch. An
interesting element of this profile is constant drug delivery, which may
avoid pulsatile dopaminergic stimulation, which has been postulated to
be related to the development of motor complications.
OBJECTIVE: To
consider the evidence surrounding the profile of rotigotine and, in
particular, whether its constant delivery system offers significant
benefits to the treatment of early and advanced PD.
METHODS: Source
material was identified using a PubMed search for the term 'rotigotine'
(up to March 2008). The review focuses only on publications related to
the rotigotine indication for PD.
RESULTS/CONCLUSION: The
rotigotine transdermal patch demonstrates clinical efficacy, alongside a
tolerability profile that appears to be well within the range of that
observed with other non-ergot dopamine agonists. The once-daily patch
formulation may favour compliance but, in similarity with the other
theoretical advantages of constant drug delivery (for example reduced
emergence of motor complications, improved tolerance to peripheral AEs),
requires further detailed study.